Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 13, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$22.1B
sum of reported positions
Reported positions
660
Changes vs prior quarter
624
41 new · 54 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 354 measured positions in 8 quarters, the typical new or larger position finished +0.0 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $19.2B | $22.1B |
| Positions | 673 | 660 |
| Biggest line | — | NVIDIA 6% |
| 2.62M |
| $936M |
| 4.2% |
| 1.69M | $639M | 2.9% |
| 2.6M | $618M | 2.8% |
| 423K | $488M | 2.2% |
| 402K | $482M | 2.2% |
| 658K | $382M | 1.7% |
| 963K | $328M | 1.5% |
| 713K | $309M | 1.4% |
| 843K | $297M | 1.3% |
| 1.16M | $293M | 1.3% |
| 606K | $289M | 1.3% |
| 761K | $229M | 1.0% |
| 644K | $221M | 1.0% |
| 379K | $194M | 0.9% |
| 1.42M | $182M | 0.8% |
| 1.35M | $179M | 0.8% |
| 544K | $178M | 0.8% |
| 2.01M | $176M | 0.8% |
| 347K | $174M | 0.8% |
| 429K | $171M | 0.8% |
| 210K | $159M | 0.7% |
| 271K | $152M | 0.7% |
Trevi Therapeutics (TRVI)
774K → 966K shares (+25%)
Celldex Therapeutics (CLDX)
279K → 481K shares (+73%)
Air Products (APD)
41K → 61K shares (+49%)
AppLovin (APP)
79K → 34K shares (−56%)
Mercadolibre (MELI)
19K → 10K shares (−46%)
Magna International (MGA)
297K → 267K shares (−10%)
Robinhood Markets (HOOD)
68K → 169K shares (+148%)
Ciena (CIEN)
11K → 34K shares (+206%)
Newmont (NEM)
168K → 172K shares (+2%)
ATAIBECKLEY INC
3.09M → 3.04M shares (−2%)
Mbx Biosciences (MBX)
294K → 290K shares (−2%)
Warner Music Group (WMG)
545K → 591K shares (+9%)
Qualcomm (QCOM)
90K → 86K shares (−5%)
Corning Inc. (GLW)
67K → 62K shares (−8%)
Stoke Therapeutics (STOK)
502K → 480K shares (−4%)
Valero Energy (VLO)
101K → 60K shares (−40%)
Starbucks (SBUX)
147K → 153K shares (+4%)
Boston Scientific (BSX)
1.26M → 367K shares (−71%)
IDEX Corporation (IEX)
66K → 69K shares (+5%)
Amphenol (APH)
84K → 85K shares (+1%)
Moonlake Immunotherapeutics (MLTX)
818K → 770K shares (−6%)
Legend Biotech (LEGN)
470K → 505K shares (+7%)
Rapport Therapeutics (RAPP)
186K → 348K shares (+87%)
Immunome (IMNM)
540K → 680K shares (+26%)
Cloudflare (NET)
61K → 58K shares (−4%)
